FDA Fast-Tracks Approval of Promising Drug for Alzheimer’s Disease

Alzheimer’s patients are praising the FDA’s approval of a groundbreaking drug that scientists say has shown to delay symptoms of the disease. Susie Mitchell tells CBS News she’s experienced promising results using Leqembi. The drug reduces amyloid beta plaque in the brain, according to the FDA, which is a marker for Alzheimer’s. Mitchell’s husband says he hasn’t seen her symptoms worsening. Inside Edition Digital’s Mara Montalbano has more.